GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Microbot Medical Inc (NAS:MBOT) » Definitions » Peter Lynch Fair Value

MBOT (Microbot Medical) Peter Lynch Fair Value : $-7.11 (As of Oct. 31, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Microbot Medical Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Here, as of today, Microbot Medical's PEG is 1. Microbot Medical's 5-Year TTM EBITDA Growth Rate is 8.78. Microbot Medical's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 was $-0.81. Therefore, the Peter Lynch Fair Value for today is $-7.11.

As of today (2024-10-31), Microbot Medical's share price is $0.9548. Microbot Medical's Peter Lynch fair value is $-7.11. Therefore, Microbot Medical's Price to Peter Lynch Fair Value Ratio for today is N/A.


The historical rank and industry rank for Microbot Medical's Peter Lynch Fair Value or its related term are showing as below:



MBOT's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.64
* Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Microbot Medical Peter Lynch Fair Value Historical Data

The historical data trend for Microbot Medical's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microbot Medical Peter Lynch Fair Value Chart

Microbot Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Peter Lynch Fair Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Microbot Medical Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Microbot Medical's Peter Lynch Fair Value

For the Medical Instruments & Supplies subindustry, Microbot Medical's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Microbot Medical's Price-to-Peter-Lynch-Fair-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Microbot Medical's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Microbot Medical's Price-to-Peter-Lynch-Fair-Value falls into.



Microbot Medical Peter Lynch Fair Value Calculation

Microbot Medical's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* 8.78 *-0.81
=-7.11

Microbot Medical's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.81.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


Microbot Medical  (NAS:MBOT) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 8.78 instead of 15 in this case.

Microbot Medical's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=0.9548/-7.11
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Microbot Medical Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of Microbot Medical's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Microbot Medical Business Description

Traded in Other Exchanges
Address
288 Grove Street, Suite 388, Braintree, MA, USA, 02184
Microbot Medical Inc is a pre-clinical medical device company. It specializes in developing next-generation micro-robotic medical technologies that can change the future of medicine. Their vision is to improve the quality of life of millions of patients globally by advancing micro-robotic technologies to perform surgical procedures and offer physicians and their patients less invasive and more precise solutions. The company's innovative platforms LIBERTY and Self-Cleaning Shunt (SCS) are in one of the fastest-growing segments in healthcare. The group continuously develops its technology with the goal to improve surgical outcomes worldwide. The firm presently holds domestic and global patents that strengthen its product portfolio and create barriers of entry.
Executives
Rachel Vaknin officer: Chief Financial Officer DROR 3/10, ZICHRON YAAKOV L3 3090216
Simon Sharon officer: General Manager & CTO 8 HAMADA STREET, ZICHRON YAACOV L3 3090708
Yoseph Bornstein director, 10 percent owner 16 IRUS STREET, ROSH HA'AYIN L3 4858022
Tal Baruch Wenderow director 1149, BEACON STREET, NEWTON MA 02461
Eyal Morag officer: Chief Medical Officer BONEY HAEAR 3 STREET, APT #13, TEL AVIV L3 6937303
Aileen Ptucha Stockburger director 26 WELLINGTON CT, BELLE MEADE NJ 08502
Harel Gadot director, 10 percent owner, officer: Chairman and CEO 5 VILLAGE LANE, HINGHAM MA 02043
Joseph Mona 10 percent owner 808 HAMPTON ST, COLUMBIA SC 29201
Prattipati Laxminarain director 3 HEWINS FARM ROAD, WELLESLEY MA 02481
Yoav Zvi Waizer director 8 HAVERED STREET, RAANANA L3 4352308
Moshe Shoham director 22 BEDOLACH STREET, HOSHAYA L3 1791500
Leon Lewkowicz 10 percent owner GORDON STREET 10, APARTMENT 7, TEL-AVIV L3 63458
Martin J. Madden director C/O MICROBOT MEDICAL INC., 175 DERBY STREET 27/1, HINGHAM MA 02043
Yehezkel Himelfarb officer: General Manager & COO 32 BEN YOSEF STREET, TEL-AVIV L3 6912530
Sandra Berkson 10 percent owner C/O SABER HOLDING GMBH, WEIN KRUMMBAUMGASSE C4 1020